About Taste receptor type 2 member 20
Taste receptor type 2 member 20 (TAS2R20) is a protein
from Homo sapiens identified by UniProt accession
P59543, 309 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | Taste receptor type 2 member 20 |
| UniProt accession | P59543 |
| Gene | TAS2R20 |
| Organism | Homo sapiens |
| Length | 309 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (16)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.22
- lung adenocarcinoma · score 0.18
- breast adenocarcinoma · score 0.16
- squamous cell lung carcinoma · score 0.13
- head and neck squamous cell carcinoma · score 0.13
- sensory perception of bitter taste · score 0.12
- Familial prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- blood protein measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P59543-F1 | alphafold | PREDICTED | 87.15 | — |
Amino-acid sequence (309 residues)
MMSFLHIVFS ILVVVAFILG NFANGFIALI NFIAWVKRQK ISSADQIIAA LAVSRVGLLW VILLHWYSTV LNPTSSNLKV IIFISNAWAV TNHFSIWLAT SLSIFYLLKI VNFSRLIFHH LKRKAKSVVL VIVLGSLFFL VCHLVMKHTY INVWTEECEG NVTWKIKLRN AMHLSNLTVA MLANLIPFTL TLISFLLLIY SLCKHLKKMQ LHGKGSQDPS TKIHIKALQT VTSFLILLAI YFLCLIISFW NFKMRPKEIV LMLCQAFGII YPSFHSFILI WGNKTLKQTF LSVLWQVTCW AKGQNQSTP
Explore Taste receptor type 2 member 20 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets